(Total Views: 60)
Posted On: 12/10/2024 8:07:42 AM
Post# of 98152
BNCM: DELEX PHARMA Bolsters Market Reach Through 6 Major Conventions in November 2024
Press Release | 12/10/2024
Delex Pharma International, Inc. (Delex Pharma) strengthened its market presence in 2024 by complementing its digital initiatives, such as the ICU Forum, with participation in six major on-ground conventions, the majority of which took place in November 2024. Additionally, we have conducted hybrid webinars and events with forty-four (44) partner medical societies and hospital departments. These events target key healthcare professionals across multiple specialties, enhancing brand visibility and engagement.
Penetrating the Anesthesia Market
Delex Pharmas Anesthesia business unit achieved 37% growth this year and further solidified its market reach at the 2024 Annual Convention and Postgraduate Course Scientific Program, held from November 27 to 29, 2024, at the Marriott Grand Ballroom in Pasay City. Engaging nearly 3,000 anesthesiologists, Delex Pharma showcased its broadened anesthesia portfolio, including intravenous solutions like Ibuprofen (Intrafen), Paracetamol (Ifimol), Propofol (Delexofol), and Dexmedetomidine Hydrochloride (Predex). Meanwhile, Ibuprofen (Intrafen) is an innovator brand and the first and only IV Ibuprofen in the Philippines, launched in August 2018, with significant sales opportunities anticipated.
The company also highlighted new offerings such as Etoricoxib (Exib 120 and 90), which is an oral medicine, and Fentanyl (Fentalex), a transdermal patch, addressing the growing demand for anesthesia innovations in the Philippines. Similarly, Verathons GlideScope, a video-assisted laryngoscopy tool, was also highlighted. This invaluable device continues to see growing demand for airway management among anesthesiologists in various clinical settings.
Link to Video: https://delexhealth.com/delex-psa-annual-convention-2024/
Cultivating Bonds with Hospital Decision-Makers
To magnify our pharmaceutical and medical device businesses, we actively promoted our diverse product portfolioranging from critical care, anesthesia, anti-infectives, oncology, medical devices, and womens healthduring the Philippine Hospital Administrators (PHA) Convention held at the Manila Hotel from November 20 to 22, 2024. Our team engaged with nearly 2,000 decision-makers and top executives, including chief executive officers (CEOs), hospital administrators, medical directors, chief nursing officers (CNOs), finance managers, and procurement heads, fostering meaningful business connections.
Furthermore, we broke new ground in promotional efforts by engaging hospital administrators at the Philippine College of Hospital Administrators (PHA) event, also held at the Manila Hotel, from November 15 to 17, 2024. This initiative further reinforced our commitment to building strategic partnerships within the healthcare industry, augmenting sales opportunities for Delex Pharma.
Strengthening Relationships with Obstetricians
To capture the obstetric market, Delex Pharma engaged over 5,000 obstetricians, department heads, and medical society leaders at the Philippine Obstetrical and Gynecological Society Annual Convention from November 13 to 15, 2024, at the PICC in Pasay City. Additional promotions occurred during the Philippine Society of Maternal Fetal Medicine Convention on November 29 to 30, 2024, at the Novotel Hotel in Quezon City.
The company introduced products like Labetalol Hydrochloride (Betalex), Philips Lumify, Clotrimazole (Vagison SG 100), and OBNate IQ Plus, strategically targeting the Philippines' growing obstetric devices and ICU market. Projections indicate the market could grow from $1,995 million in 2023 to $3,795 million by 2029.
Expanding Promotion in Cardiology
As the treatment of cardiovascular diseases in the Philippines is projected to grow at a CAGR of 9.23% (2024-2029), reaching a market volume of $2.13 billion by 2029, Delex Pharma intensified its efforts to connect with cardiologists. The company participated in PSE and ECHO ASIA 2024: Navigating the Future of Echocardiography convention, held from September 19 to 21, 2024, at EDSA Shangri-La Manila. Delex Pharma booth featured its Philips Medical device portfolio, drawing significant interest from cardiologists.
Driving Sales Growth Through Strategic Convention Engagements
By leveraging these conventions, Delex Pharma aims to deepen relationships with healthcare professionals and broaden its market reach across anesthesia, obstetrics, and cardiology sectors. These initiatives are expected to drive the company's sales growth and solidify its leadership in the healthcare industry.
About Bounce Mobile Systems, Inc. (OTC: BNCM)
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and listing on the OTC or NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country's economy, and bring greater social change.
For more information, visit: https://www.bncm.net/
About Delex Healthcare Group, Inc. (DELEX)
DELEX is a Delaware-registered company engaged in the development and distribution of pharmaceutical and healthcare products through its associate channels, Delex Pharma, in collaboration with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc. DELEX focuses on delivering high-quality products across various sectors of the healthcare industry by leveraging its extensive network and strategic partnerships. Together with its associates, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence.
For more information, visit: https://delexhealth.com
Press Release | 12/10/2024
Delex Pharma International, Inc. (Delex Pharma) strengthened its market presence in 2024 by complementing its digital initiatives, such as the ICU Forum, with participation in six major on-ground conventions, the majority of which took place in November 2024. Additionally, we have conducted hybrid webinars and events with forty-four (44) partner medical societies and hospital departments. These events target key healthcare professionals across multiple specialties, enhancing brand visibility and engagement.
Penetrating the Anesthesia Market
Delex Pharmas Anesthesia business unit achieved 37% growth this year and further solidified its market reach at the 2024 Annual Convention and Postgraduate Course Scientific Program, held from November 27 to 29, 2024, at the Marriott Grand Ballroom in Pasay City. Engaging nearly 3,000 anesthesiologists, Delex Pharma showcased its broadened anesthesia portfolio, including intravenous solutions like Ibuprofen (Intrafen), Paracetamol (Ifimol), Propofol (Delexofol), and Dexmedetomidine Hydrochloride (Predex). Meanwhile, Ibuprofen (Intrafen) is an innovator brand and the first and only IV Ibuprofen in the Philippines, launched in August 2018, with significant sales opportunities anticipated.
The company also highlighted new offerings such as Etoricoxib (Exib 120 and 90), which is an oral medicine, and Fentanyl (Fentalex), a transdermal patch, addressing the growing demand for anesthesia innovations in the Philippines. Similarly, Verathons GlideScope, a video-assisted laryngoscopy tool, was also highlighted. This invaluable device continues to see growing demand for airway management among anesthesiologists in various clinical settings.
Link to Video: https://delexhealth.com/delex-psa-annual-convention-2024/
Cultivating Bonds with Hospital Decision-Makers
To magnify our pharmaceutical and medical device businesses, we actively promoted our diverse product portfolioranging from critical care, anesthesia, anti-infectives, oncology, medical devices, and womens healthduring the Philippine Hospital Administrators (PHA) Convention held at the Manila Hotel from November 20 to 22, 2024. Our team engaged with nearly 2,000 decision-makers and top executives, including chief executive officers (CEOs), hospital administrators, medical directors, chief nursing officers (CNOs), finance managers, and procurement heads, fostering meaningful business connections.
Furthermore, we broke new ground in promotional efforts by engaging hospital administrators at the Philippine College of Hospital Administrators (PHA) event, also held at the Manila Hotel, from November 15 to 17, 2024. This initiative further reinforced our commitment to building strategic partnerships within the healthcare industry, augmenting sales opportunities for Delex Pharma.
Strengthening Relationships with Obstetricians
To capture the obstetric market, Delex Pharma engaged over 5,000 obstetricians, department heads, and medical society leaders at the Philippine Obstetrical and Gynecological Society Annual Convention from November 13 to 15, 2024, at the PICC in Pasay City. Additional promotions occurred during the Philippine Society of Maternal Fetal Medicine Convention on November 29 to 30, 2024, at the Novotel Hotel in Quezon City.
The company introduced products like Labetalol Hydrochloride (Betalex), Philips Lumify, Clotrimazole (Vagison SG 100), and OBNate IQ Plus, strategically targeting the Philippines' growing obstetric devices and ICU market. Projections indicate the market could grow from $1,995 million in 2023 to $3,795 million by 2029.
Expanding Promotion in Cardiology
As the treatment of cardiovascular diseases in the Philippines is projected to grow at a CAGR of 9.23% (2024-2029), reaching a market volume of $2.13 billion by 2029, Delex Pharma intensified its efforts to connect with cardiologists. The company participated in PSE and ECHO ASIA 2024: Navigating the Future of Echocardiography convention, held from September 19 to 21, 2024, at EDSA Shangri-La Manila. Delex Pharma booth featured its Philips Medical device portfolio, drawing significant interest from cardiologists.
Driving Sales Growth Through Strategic Convention Engagements
By leveraging these conventions, Delex Pharma aims to deepen relationships with healthcare professionals and broaden its market reach across anesthesia, obstetrics, and cardiology sectors. These initiatives are expected to drive the company's sales growth and solidify its leadership in the healthcare industry.
About Bounce Mobile Systems, Inc. (OTC: BNCM)
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and listing on the OTC or NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country's economy, and bring greater social change.
For more information, visit: https://www.bncm.net/
About Delex Healthcare Group, Inc. (DELEX)
DELEX is a Delaware-registered company engaged in the development and distribution of pharmaceutical and healthcare products through its associate channels, Delex Pharma, in collaboration with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc. DELEX focuses on delivering high-quality products across various sectors of the healthcare industry by leveraging its extensive network and strategic partnerships. Together with its associates, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence.
For more information, visit: https://delexhealth.com
(0)
(0)Scroll down for more posts ▼
